Contrast Agents and Radiopharmaceuticals – Market Insights – United States

The US contrast agents and radiopharmaceutical market will see moderate growth over the forecast period. Market growth will be driven by rising PET and MRI procedure volumes, and the expanding use of imaging agents in CEUS and PET procedures. However, the market will be somewhat limited by the continued concern over gadolinium and radiation exposure in certain modalities. Additionally, the shift toward value-based care will act as a barrier for certain procedures, favoring those that offer the highest levels of accuracy and clarity in visualization instead. Moving forward, market growth will be driven by the introduction of new contrast agents currently in development or undergoing clinical trials, along with FDA approvals for expanded indications of existing contrast agents.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for contrast agents and radiopharmaceuticals in the US from 2019 through 2033.

There has been a gradual increase in the number FDA approvals for PSMA PET imaging agents.

Which PET imaging agents have received FDA approval?

What advantages do these PSMA PET imaging agents offer?

What indications are they approved for?

Manufacturers are actively engaging in ongoing clinical evaluation of their contrast agent products.

Which contrast agent products are under clinical evaluation?

What advantage do they offer over the existing contrast agents in the market.

The FDA expanded approval for the use of CEUS in radiology procedures.

What type of procedures does this approval extend to? What additional procedures could be approved in the future?

Which contrast agents have received FDA approval?

How will these FDA approvals change the competitive landscape.

Looming concerns over the effects of gadolinium retention will negatively affect the use of contrast-enhanced MRI.

How are ACOs, health networks, and physicians responding to the recent findings on gadolinium retention?

What are the key differences between linear and macrocyclic GBCAs, and how will market demand for these products shift going forward?

Will other imaging modalities cannibalize contrast-enhanced MRI procedures?

Which companies (and associated products) will benefit from the shift to macrocyclic GBCAs?